Welcome to
Sanofi in Canada
Toggle navigation
About Us
Science & Innovation
Products and Resources
Patient Support
Our Responsibility
Careers
Media
Toggle navigation
News Releases
Subscribe
Media Contacts
Social Media
News
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Subscribe
Year
All Years
2023
2022
2021
2020
2019
2018
2017
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Photos
Video
Audio
Documents
Events
Standard
Nov 22, 2019
Sanofi Canada named one of Canada's Top 100 Employers for 2020
Oct 22, 2019
Patients in Quebec now have access to DUPIXENT™ for the treatment of moderate-to-severe atopic dermatitis
Oct 18, 2019
Sanofi to conduct precautionary voluntary recall of Zantac OTC in Canada and the U.S.
Photos
1
Oct 1, 2019
"Pillars of Strength" photo exhibit opens to celebrate National Seniors Day with compelling images of Canadian Seniors
Sep 27, 2019
Health Canada approves Dupixent™ as the first biologic for the treatment of adolescents with moderate-to-severe atopic dermatitis
Sep 26, 2019
Sanofi Canada receives Gold-Level Parity Certification
Photos
1
Jun 11, 2019
Canadian employers underestimate the presence of chronic disease in the workforce
Apr 11, 2019
Health Canada issues Notice of Compliance with Conditions (NOC/c) for LibtayoTM (cemiplimab), the first and only biologic for the treatment of advanced cutaneous squamous cell carcinoma (CSCC)
Oct 17, 2018
Canadians are invited to join the conversation: Raise Your Hand for Diabetes
Oct 1, 2018
Sanofi aims to topple the flu as it marks National Seniors Day with a Guinness World Record attempt
Sep 27, 2018
Canadians living with diabetes in Ontario and Manitoba now have greater access to diabetes medicine
Sep 25, 2018
Health Canada approves Lovenox® for the prevention of blood clot formation in the extra-corporeal circulation during hemodialysis in patients with end stage kidney disease (ESKD)
Studies show that Lovenox® (enoxaparin sodium) is an alternative to conventional heparin in preventing clotting during hemodialysis
Jul 10, 2018
Sanofi denounces CADTH negative recommendation that could limit treatment options for Canadians with atopic dermatitis
Jul 3, 2018
Three Canadian Researchers Receive Sanofi–CARO Award for Research in Prostate Cancer Therapies
Jun 27, 2018
Sanofi presents results from the first head-to-head study comparing Toujeo® to insulin degludec
Jun 22, 2018
Sanofi Canada Lends Support in the Fight to Eradicate Tuberculosis in Canada
Jun 13, 2018
Canadian employers underestimate the proportion of their workforce with a chronic condition and its impact
Jun 8, 2018
Canadian science prodigy winner of prestigious international competition
May 16, 2018
Canadians living with diabetes can now access a new resource to help better manage their disease
Apr 12, 2018
Sanofi to invest €350 million in Canadian vaccine facility
Apr 12, 2018
Sanofi to invest €350 million in Canadian vaccine facility
* Expansion demonstrates company’s commitment to innovation and leadership in global public health
Apr 12, 2018
New tools, support and information on insulin use now available to Canadians living with Type 2 diabetes aiming to maintain healthy blood glucose levels
Apr 11, 2018
/R E P E A T -- Media Advisory - Sanofi to announce significant investment in Canadian vaccine production facility/
Apr 10, 2018
Media Advisory - Sanofi to announce significant investment in Canadian vaccine production facility
Mar 10, 2018
Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate
Show
5
10
25
50
100
per page
«
1
2
3
4
»